FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950374384> ?p ?o ?g. }

• W2950374384 abstract "Bicyclol, the most commonly-used liver hepatoprotective drug in China, is often selected to control disease progression in CHB patients who refuse anti-viral treatment. However, data on histological changes after bicyclol treatment in these patients are scarce. Therefore, this study has been conducted to find out whether bicyclol has good benefits of histological improvement in CHB patients who refuse anti-viral agents. The demographic, clinical and pathological data were collected from CHB patients who received bicyclol from January 2010 to June 2016. Improvement in liver inflammation or fibrosis is defined as at least one-grade or one-stage decrease as measured by the Scheuer scoring system. Thirty patients treated with ETV for 48 weeks were chosen as a control group to compare the histological improvement between bicyclol and entecavir (ETV) after 48-week treatment. A total of 123 patients with CHB treated with bicyclol were included in this study. Paired liver biopsies were performed in 70 patients. Inter-biopsy interval was 17.44 ± 8.90 months (12–60 months). As shown by facts, 41.4% patients achieved liver inflammation improvement, while only 10.0% patients showed liver inflammation progression after bicyclol treatment. In regarding to liver fibrosis, as shown by facts, 28.6% patients achieved fibrosis improvement. More importantly, It was found that the proportions of patients with liver inflammation and fibrosis improvement were both not significantly lower than those in ETV group (53.3% vs 63.3 and 36.7% vs 43.4%). Most of patients (82.4%) with elevated baseline ALT became normal after bicyclol treatment. More importantly, as shown by the multi-variate analysis, the treatment course of bicyclol was an independent factor for liver inflammation improvement. With the HBeAg status adjusted, ALT and HBV-DNA quantity, the odds ratio (95% confidence interval) of patients with ≥48-week treatment was 5.756 (1.893,17.500) when compared with patients via < 48-week treatment. Bicyclol can improve liver inflammation and the ALT normalization rate of CHB patients, especially when the treatment course is prolonged. This has confirmed that bicyclol could control hepatitis activity, which might be a good choice for CHB patients who refuse anti-viral treatments." @default.
• W2950374384 created "2019-06-27" @default.
• W2950374384 creator A5014741298 @default.
• W2950374384 creator A5016431737 @default.
• W2950374384 creator A5017479237 @default.
• W2950374384 creator A5019272471 @default.
• W2950374384 creator A5040154664 @default.
• W2950374384 creator A5047327817 @default.
• W2950374384 creator A5061489113 @default.
• W2950374384 creator A5067128890 @default.
• W2950374384 creator A5077410670 @default.
• W2950374384 creator A5078978295 @default.
• W2950374384 creator A5087791506 @default.
• W2950374384 date "2019-06-13" @default.
• W2950374384 modified "2023-10-10" @default.
• W2950374384 title "Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience" @default.
• W2950374384 cites W2010184652 @default.
• W2950374384 cites W2039861850 @default.
• W2950374384 cites W2104389844 @default.
• W2950374384 cites W2155510029 @default.
• W2950374384 cites W2156895759 @default.
• W2950374384 cites W2173698250 @default.
• W2950374384 cites W2238425470 @default.
• W2950374384 cites W2285637504 @default.
• W2950374384 cites W2339258848 @default.
• W2950374384 cites W2395913822 @default.
• W2950374384 cites W2404861122 @default.
• W2950374384 cites W2411781968 @default.
• W2950374384 cites W2525761015 @default.
• W2950374384 cites W3030920170 @default.
• W2950374384 cites W4211026375 @default.
• W2950374384 doi "https://doi.org/10.1186/s12876-019-1005-1" @default.
• W2950374384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6567540" @default.
• W2950374384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31196030" @default.
• W2950374384 hasPublicationYear "2019" @default.
• W2950374384 type Work @default.
• W2950374384 sameAs 2950374384 @default.
• W2950374384 citedByCount "6" @default.
• W2950374384 countsByYear W29503743842020 @default.
• W2950374384 countsByYear W29503743842021 @default.
• W2950374384 countsByYear W29503743842022 @default.
• W2950374384 crossrefType "journal-article" @default.
• W2950374384 hasAuthorship W2950374384A5014741298 @default.
• W2950374384 hasAuthorship W2950374384A5016431737 @default.
• W2950374384 hasAuthorship W2950374384A5017479237 @default.
• W2950374384 hasAuthorship W2950374384A5019272471 @default.
• W2950374384 hasAuthorship W2950374384A5040154664 @default.
• W2950374384 hasAuthorship W2950374384A5047327817 @default.
• W2950374384 hasAuthorship W2950374384A5061489113 @default.
• W2950374384 hasAuthorship W2950374384A5067128890 @default.
• W2950374384 hasAuthorship W2950374384A5077410670 @default.
• W2950374384 hasAuthorship W2950374384A5078978295 @default.
• W2950374384 hasAuthorship W2950374384A5087791506 @default.
• W2950374384 hasBestOaLocation W29503743841 @default.
• W2950374384 hasConcept C126322002 @default.
• W2950374384 hasConcept C146357865 @default.
• W2950374384 hasConcept C151730666 @default.
• W2950374384 hasConcept C203014093 @default.
• W2950374384 hasConcept C2522874641 @default.
• W2950374384 hasConcept C2775934546 @default.
• W2950374384 hasConcept C2776175608 @default.
• W2950374384 hasConcept C2776914184 @default.
• W2950374384 hasConcept C2777072776 @default.
• W2950374384 hasConcept C2777766500 @default.
• W2950374384 hasConcept C2777869810 @default.
• W2950374384 hasConcept C2780559512 @default.
• W2950374384 hasConcept C2780593183 @default.
• W2950374384 hasConcept C41260117 @default.
• W2950374384 hasConcept C71924100 @default.
• W2950374384 hasConcept C86803240 @default.
• W2950374384 hasConcept C90924648 @default.
• W2950374384 hasConceptScore W2950374384C126322002 @default.
• W2950374384 hasConceptScore W2950374384C146357865 @default.
• W2950374384 hasConceptScore W2950374384C151730666 @default.
• W2950374384 hasConceptScore W2950374384C203014093 @default.
• W2950374384 hasConceptScore W2950374384C2522874641 @default.
• W2950374384 hasConceptScore W2950374384C2775934546 @default.
• W2950374384 hasConceptScore W2950374384C2776175608 @default.
• W2950374384 hasConceptScore W2950374384C2776914184 @default.
• W2950374384 hasConceptScore W2950374384C2777072776 @default.
• W2950374384 hasConceptScore W2950374384C2777766500 @default.
• W2950374384 hasConceptScore W2950374384C2777869810 @default.
• W2950374384 hasConceptScore W2950374384C2780559512 @default.
• W2950374384 hasConceptScore W2950374384C2780593183 @default.
• W2950374384 hasConceptScore W2950374384C41260117 @default.
• W2950374384 hasConceptScore W2950374384C71924100 @default.
• W2950374384 hasConceptScore W2950374384C86803240 @default.
• W2950374384 hasConceptScore W2950374384C90924648 @default.
• W2950374384 hasIssue "1" @default.
• W2950374384 hasLocation W29503743841 @default.
• W2950374384 hasLocation W29503743842 @default.
• W2950374384 hasLocation W29503743843 @default.
• W2950374384 hasLocation W29503743844 @default.
• W2950374384 hasOpenAccess W2950374384 @default.
• W2950374384 hasPrimaryLocation W29503743841 @default.
• W2950374384 hasRelatedWork W1471480765 @default.
• W2950374384 hasRelatedWork W1983563581 @default.
• W2950374384 hasRelatedWork W2002190078 @default.
• W2950374384 hasRelatedWork W2027011970 @default.
• W2950374384 hasRelatedWork W2376621382 @default.

• next